The 340B Drug Pricing Program, long seen as a financial pillar for safety-net hospitals, is now facing growing scrutiny. A recent executive order and an unflattering congressional report have reignited debate over the program’s role, effectiveness, and oversight.
At the core of the deliberation is a question plan sponsors and policymakers care deeply about: Are the 340B dollars producing value for patients or not?
What Is 340B?
The 340B program was created by Congress in 1992 to help hospitals and clinics serving low-income populations save on drug costs by a substantial margin. The law requires drug manufacturers to sell outpatient medications at steep discounts (25–50% off) to qualifying providers, known as covered entities.
These include:
- Disproportionate Share Hospitals (DSHs)
- Federally Qualified Health Centers (FQHCs)
- Rural hospitals and clinics
- HIV/AIDS and family planning clinics
Covered entities can use the savings at their discretion: to expand services, subsidize care costs, or support operational budgets. Patients don’t access the program directly; benefits are realized through the providers that serve them.
What 340B Revenue Funds in the Real World
For many health systems, 340B revenue supports essential functions. For example, the Franciscan Missionaries of Our Lady Health System in Louisiana, 340B saves them $120 million annually, helping offset the cost of caring for the uninsured and underinsured.
But as the program has expanded, questions have emerged about whether the savings are consistently reaching the intended beneficiaries. And unlike most federally supported programs, 340B does not require reporting on how the funds are used.
Recent Developments: Executive Order & Senate Report
Executive Action
On April 15, President Trump issued an Executive Order, “Lowering Drug Prices By Once Again Putting Americans First,” aimed at adjusting Medicare outpatient drug payments to reflect 340B discounts. Supporters say the move will lower patient cost-sharing and increase pricing fairness.
Not all stakeholders agree. Hospital groups warn the policy could destabilize safety-net providers already operating on thin margins, especially if it’s paired with site-neutral payment reforms.
Congressional Scrutiny
Senator Bill Cassidy (R-La.), Chair of the Senate HELP Committee, recently released a report after investigating the program’s financial practices. His findings:
- Transparency gaps: Some hospitals generated substantial revenue from 340B without clear reinvestment in patient services.
- Oversight challenges: Contract pharmacies and third-party relationships complicate accountability.
- Patient benefit not guaranteed: In many cases, there’s no requirement that savings reduce patient costs.
Cassidy’s recommendations include:
- Mandatory reporting on how 340B revenue is used
- Clearer definitions of eligible patient benefit
- Greater transparency in contract pharmacy arrangements
Plan Sponsors Are Paying Attention
Whether 340B is reformed, preserved, or reshaped, the larger issue remains: transparent, accountable, and clinically sound sustainable drug cost solutions are desperately needed.
For plan sponsors, the risks of inefficiency and misaligned incentives are clear. Drug discounts and payment adjustments only work if they’re applied consistently, and if they translate into meaningful savings for patients and purchasers alike.
The RazorMetrics Approach: Smarter Savings, Built for Transparency
While policymakers work to realign 340B, RazorMetrics is already solving for the same underlying goals with greater precision and fewer tradeoffs.
We help plan sponsors and health systems lower drug costs by identifying clinically appropriate, lower-cost alternatives. Our platform delivers physician-approved cost-savings without interrupting care or relying on blunt reimbursement cuts.
- Physician-first model: All changes are initiated with prescriber approval
- No workflow disruption: No point-of-care pressure, no added burden
- Measurable ROI: Shared savings for plan sponsors and members alike
At a time when every dollar in the healthcare system is getting stretched, RazorMetrics brings clarity, control, and confidence to drug spending.
340B reform is coming. Whether it strengthens or limits the program, the broader imperative is clear, cost containment must be strategic, data-driven, and effective. RazorMetrics is built to meet that standard, and to help plan sponsors lead with value.
